Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1243 | Discontinuation of anti-TNF treatment Wiki | 1.00 |
| drug1236 | Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally AND Standard of care Wiki | 1.00 |
| drug3738 | Standard of care Wiki | 0.20 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D009336 | Necrosis NIH | 0.71 |
| D014456 | Ulcer NIH | 0.30 |
| D003092 | Colitis NIH | 0.30 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0002583 | Colitis HPO | 0.30 |
| HP:0100279 | Ulcerative colitis HPO | 0.30 |
Navigate: Correlations HPO
There is one clinical trial.
The primary objective is to assess if discontinuation of anti- tumor necrosis factor alpha (TNF) treatment in ulcerative colitis patients in sustained clinical remission, with the option to restart treatment in the case of relapse, is non-inferior to continued anti-TNF treatment. Secondary objectives are to assess the efficacy and safety of restarting anti-TNF treatment after a relapse
Description: Remission confirmed endoscopically by mucosal healing defined as Mayo Endoscopic Subscore (MES) score 0 or 1 after 2 years of randomized treatment
Measure: Proportion of patients in sustained clinical remission Time: 2 yearsDescription: Remission confirmed endoscopically by mucosal healing defined as Mayo Endoscopic Subscore (MES) score 0 or 1 after 4 years of randomized treatment
Measure: Proportion of patients in sustained clinical remission Time: 4 yearsDescription: Relapse time
Measure: Time from randomization to relapse Time: 2 yearsDescription: Relapse time
Measure: Time from randomization to relapse Time: 4 yearsDescription: Remission, but no need to restart anti-tnf therapy
Measure: Proportion of patients who are no longer in remission, but who do not need to restart anti-tumor necrosis factor (TNF) therapy Time: 2 yearsDescription: Remission, but no need to restart anti-tnf therapy
Measure: Proportion of patients who are no longer in remission, but who do not need to restart anti-tumor necrosis factor (TNF) therapy Time: 4 yearsDescription: Remission after relapse
Measure: Proportion of relapse patients achieving remission after anti-TNF restart Time: 2 yearsDescription: Remission after relapse
Measure: Proportion of relapse patients achieving remission after anti-TNF restart Time: 4 yearsDescription: Adverse events
Measure: Adverse events and serious adverse events frequency and severity Time: 2 yearsDescription: Adverse events
Measure: Adverse events and serious adverse events frequency and severity Time: 4 yearsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports